Research focusing on lncRNAs, such as prostate cancer antigen 3 (PCA3) (13) and metastasis associated lung adenocarcinoma transcript 1 (MALAT1) (14), may improve current screening techniques to identify patients at risk for PCa. This evidence concerns the gene MALAT1 and posterior cortical atrophy.